Vidofludimus
- Generic Name
- Vidofludimus
- Drug Type
- Small Molecule
- Chemical Formula
- C20H18FNO4
- CAS Number
- 717824-30-1
- Unique Ingredient Identifier
- 8Y1PJ3VG81
- Background
Vidofludimus is under investigation in clinical trial NCT03722576 (Vidofludimus Calcium for Primary Sclerosing Cholangitis).
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo matching IMU-838
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 450
- Registration Number
- NCT05054140
- Locations
- π§π¬
Dr. Penko Shotekov, Sofia, Bulgaria
π§π¬UMHAT Alexandrovska, Sofia, Bulgaria
π³π±Dr. Eva Strijibis, Amsterdam, Netherlands
IMU-838 and Oseltamivir in the Treatment of COVID-19
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2023-08-22
- Target Recruit Count
- 38
- Registration Number
- NCT04516915
- Locations
- π¬π§
University Hospital Coventry and Warwickshire NHS Trust, Coventry, West Midlands, United Kingdom
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 234
- Registration Number
- NCT04379271
- Locations
- π§π¬
Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria
π§π¬UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria
π©πͺUniversity Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany
Vidofludimus Calcium for Primary Sclerosing Cholangitis
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Elizabeth Carey
- Target Recruit Count
- 18
- Registration Number
- NCT03722576
- Locations
- πΊπΈ
Mayo Clinic in Arizona, Phoenix, Arizona, United States
πΊπΈArizona State University, Tempe, Arizona, United States
πΊπΈMayo Clinic in Rochester, Rochester, Minnesota, United States
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 263
- Registration Number
- NCT03341962
- Locations
- π²π°
University Clinic for Hematology - Skopje - Macedonian Hematology Association, Skopje, North Macedonia
πΊπΈAlliance Medical Research, LLC, Lighthouse Point, Florida, United States
πΊπΈDel Sol Research Management, LLC, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.